Perrigo Company plc Write off of Deferred Debt Issuance Cost
Perrigo Company plc (PRGO) reported Write off of Deferred Debt Issuance Cost of $10.60 million for the 9-month period ending 2017-09-30, per its 10-Q filed 2017-11-09.
Discontinued › Expense Statement › Operating Expenses
us-gaap:WriteOffOfDeferredDebtIssuanceCost · last filed 2018-11-08
- Perrigo Company plc write off of deferred debt issuance cost for the quarter ending 2017-07-01 was $10.60M.
- Perrigo Company plc write off of deferred debt issuance cost for the quarter ending 2013-12-28 was $10.50M.
- Perrigo Company plc write off of deferred debt issuance cost for fiscal 2014 was $10.50M.
| Period end | Write off of Deferred Debt Issuance Cost 3 month | Write off of Deferred Debt Issuance Cost 9 month | Write off of Deferred Debt Issuance Cost 12 month |
|---|---|---|---|
| 2017-09-30 | $10.60M 10-Q · filed 2017-11-09 | ||
| 2017-07-01 | $10.60M 10-Q · filed 2018-11-08 | ||
| 2014-06-28 | $10.50M 10-K · filed 2017-05-22 | ||
| 2013-12-28 | $10.50M 10-K · filed 2015-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |